Premium
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Author(s) -
Xia Yuqiong,
Rao Lang,
Yao Huimin,
Wang Zhongliang,
Ning Pengbo,
Chen Xiaoyuan
Publication year - 2020
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.202002054
Subject(s) - macrophage , tumor associated macrophage , immunotherapy , tumor microenvironment , cancer research , macrophage activating factor , drug delivery , microvesicles , cancer immunotherapy , metastasis , proinflammatory cytokine , cancer , immune system , inflammation , medicine , immunology , materials science , biology , lymphokine , nanotechnology , in vitro , microrna , biochemistry , gene
Macrophages play an important role in cancer development and metastasis. Proinflammatory M1 macrophages can phagocytose tumor cells, while anti‐inflammatory M2 macrophages such as tumor‐associated macrophages (TAMs) promote tumor growth and invasion. Modulating the tumor immune microenvironment through engineering macrophages is efficacious in tumor therapy. M1 macrophages target cancerous cells and, therefore, can be used as drug carriers for tumor therapy. Herein, the strategies to engineer macrophages for cancer immunotherapy, such as inhibition of macrophage recruitment, depletion of TAMs, reprograming of TAMs, and blocking of the CD47‐SIRPα pathway, are discussed. Further, the recent advances in drug delivery using M1 macrophages, macrophage‐derived exosomes, and macrophage‐membrane‐coated nanoparticles are elaborated. Overall, there is still significant room for development in macrophage‐mediated immune modulation and macrophage‐mediated drug delivery, which will further enhance current tumor therapies against various malignant solid tumors, including drug‐resistant tumors and metastatic tumors.